EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Intercept Pharmaceuticals's enterprise value is $393.4 Mil.
Intercept Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-157.2 Mil. Therefore, Intercept Pharmaceuticals's EV-to-EBITDA for today is -2.50.
The historical rank and industry rank for Intercept Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ICPT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -563.03 Med: -9.12 Max: -1.46
Current: -2.5
During the past 13 years, the highest EV-to-EBITDA of Intercept Pharmaceuticals was -1.46. The lowest was -563.03. And the median was -9.12.
ICPT's EV-to-EBITDA is ranked worse than 100% of 477
companies
in the Biotechnology industry
Industry Median: 7.17
vs ICPT: -2.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2023-06-10), Intercept Pharmaceuticals's stock price is $11.85.
Intercept Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $6.280. Therefore, Intercept Pharmaceuticals's PE Ratio for today is 1.89.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Intercept Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Intercept Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Intercept Pharmaceuticals Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
EV-to-EBITDA
-10.68
-13.13
-4.10
-7.41
-2.32
Intercept Pharmaceuticals Quarterly Data
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
EV-to-EBITDA
-11.43
-9.88
-2.47
-2.32
-2.92
Competitive Comparison
For the Biotechnology subindustry, Intercept Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercept Pharmaceuticals EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Intercept Pharmaceuticals's EV-to-EBITDA falls in comparison to its industry or sector. The grey bar indicates the EV-to-EBITDA's extreme value range as defined by GuruFocus.
Intercept Pharmaceuticals's current Enterprise Value is $393.4 Mil.
Intercept Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-157.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Intercept Pharmaceuticals's PE Ratio for today is calculated as:
Intercept Pharmaceuticals's share price for today is $11.85.
Intercept Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Intercept Pharmaceuticals EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Intercept Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Intercept Pharmaceuticals (NAS:ICPT) Business Description
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.4(3.27%) Volume: 1,047,199 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
ICPT has been successfully added to your 
